ALAMEDA, Calif.--(BUSINESS WIRE)--June 29, 2006--InSite Vision Incorporated (AMEX:ISV - News) -- an ophthalmic products company currently developing therapies that treat ocular infection, glaucoma, and retinal diseases, today announced it has submitted to the United States Food and Drug Administration (FDA) a New Drug Application (NDA) for AzaSite(TM) for the treatment of bacterial conjunctivitis. AzaSite combines a topical 1% azithromycin formulation with InSite's patented DuraSite® ophthalmic drug-delivery system that increases ocular retention of the drug.
